FILTER BY

also on other fortune lists

Change the World

Courtesy of WHO

2

Merck

MRK

U.S.

The timing was tragic. Merck embraced a vital mission in 2014 when it began developing an Ebola vaccine in collaboration with Canada’s public health agency and NewLink Genetics, not long after the deadly virus broke out in West Africa. Effective vaccines take months to create, and by the time V920 could be deployed, the disease had claimed thousands of lives.

But when the scourge rose again earlier this year, in the Democratic Republic of the Congo, Merck was ready. It shipped nearly 13,000 doses of V920 to the World Health Organization, which provided vaccinations to more than 3,300 people. The DRC’s health ministry says no vaccinated people developed the disease—and with another outbreak declared in the eastern DRC in August, Merck’s lifesaver is on the front lines once more.

Looking for leads, investment insights, or competitive intelligence?

Impact Segment

Public Health/Nutrition

Sector

Health Care

Industry

Pharmaceuticals

CEO

Kenneth Frazier

Employees

69,000

Company Type

Public

Revenues ($M) (Last Fiscal Year)

$40,122

Profits ($M) (Last Fiscal Year)

$2,394

Market Value ($M)

$177,577

News about Merck

Drugmakers Blame Middlemen for High Prices But Still Make Huge Profits

Out of more than 100 business sectors, drug companies are in the top 10 of profits.

Read More →
Fortune's Blue Ribbon Companies 2018

These 56 companies are on at least four of Fortune's 2018 rankings.

Read More →
The 5 Best Biotech and Health Care Stocks to Buy for 2019 Now That Congress Can’t Repeal Obamacare

With Congress split between Republicans and Democrats, pharma and biotech stocks are ready to surge.

Read More →